Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 13/20 | 0.79 |
| ▸ | MKNK1 | Q9BUB5 | 4/20 | 0.43 |
| ▸ | MKNK2 | Q9HBH9 | 4/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | EIF4E | P06730 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1355307 | 0.88 | ADORA2A (1.00) | ADORA2AMKNK1MKNK2HPGD | |
| SCHEMBL1355331 | 0.88 | ADORA2A (1.00) | ADORA2AMKNK1MKNK2HPGD | |
| SCHEMBL1354665 | 0.88 | ADORA2A (1.00) | ADORA2AMKNK1MKNK2HPGD | |
| SCHEMBL1355414 | 0.88 | ADORA2A (1.00) | ADORA2AMKNK1MKNK2HPGD | |
| SCHEMBL1355436 | 0.87 | ADORA2A (0.75) | ADORA2AMKNK1MKNK2HRH3HPGD | |
| SCHEMBL1355148 | 0.86 | ADORA2A (0.79) | ADORA2AMKNK1MKNK2HPGD | |
| SCHEMBL1356330 | 0.83 | ADORA2A (0.78) | ADORA2AMKNK1MKNK2HPGD | |
| SCHEMBL1355235 | 0.83 | ADORA2A (1.00) | ADORA2AMKNK1MKNK2 | |
| SCHEMBL24087336 | 0.83 | ADORA2A (0.77) | ADORA2AMKNK1MKNK2HPGD | |
| SCHEMBL1355110 | 0.81 | ADORA2A (1.00) | ADORA2AMKNK1MKNK2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9029393-B2 | Adenosine receptor ligands and uses thereof | KALDI PHARMA, SAS (FR) | 2015-05-12 | — | — | US | claimed |
| US-9029393-B2 | Adenosine receptor ligands and uses thereof | KALDI PHARMA, SAS (FR) | 2015-05-12 | — | — | US | disclosed |
| US-9029393-B2 | Adenosine receptor ligands and uses thereof | KALDI PHARMA, SAS (FR) | 2015-05-12 | — | — | US | disclosed |
| US-9029393-B2 | Adenosine receptor ligands and uses thereof | KALDI PHARMA, SAS (FR) | 2015-05-12 | — | — | US | disclosed |
| EP-2391625-B1 | New adenosine receptor ligands and uses thereof | DOMAIN THERAPEUTICS (FR) | 2013-05-01 | — | — | EP | disclosed |
| EP-2391625-B1 | New adenosine receptor ligands and uses thereof | DOMAIN THERAPEUTICS (FR) | 2013-05-01 | — | — | EP | disclosed |
| US-20110288074-A1 | NEW ADENOSINE RECEPTOR LIGANDS AND USES THEREOF | DOMAIN THERAPEUTICS (FR) | 2011-11-24 | — | — | US | disclosed |
| US-20110288074-A1 | NEW ADENOSINE RECEPTOR LIGANDS AND USES THEREOF | DOMAIN THERAPEUTICS (FR) | 2011-11-24 | — | — | US | disclosed |
| US-20110288074-A1 | NEW ADENOSINE RECEPTOR LIGANDS AND USES THEREOF | DOMAIN THERAPEUTICS (FR) | 2011-11-24 | — | — | US | disclosed |
| WO-2010084425-A1 | NEW ADENOSINE RECEPTOR LIGANDS AND USES THEREOF | DOMAIN THERAPEUTICS (FR) | 2010-07-29 | — | — | WO | disclosed |
| EP-2210891-A1 | New adenosine receptor ligands and uses thereof | Domain Therapeutics (FR) | 2010-07-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288074-A1 | NEW ADENOSINE RECEPTOR LIGANDS AND USES THEREOF | ADORA2A, ADORA1, ADORA2B | ADORA2A 1/4885MKNK1 1905/4885MKNK2 1468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.